CN113425765A - 一种降尿酸药物及其制作方法 - Google Patents
一种降尿酸药物及其制作方法 Download PDFInfo
- Publication number
- CN113425765A CN113425765A CN202110794132.6A CN202110794132A CN113425765A CN 113425765 A CN113425765 A CN 113425765A CN 202110794132 A CN202110794132 A CN 202110794132A CN 113425765 A CN113425765 A CN 113425765A
- Authority
- CN
- China
- Prior art keywords
- extract
- eurycoma longifolia
- uric acid
- semen plantaginis
- concentrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 36
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229940116269 uric acid Drugs 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000000284 extract Substances 0.000 claims abstract description 58
- 240000005739 Eurycoma longifolia Species 0.000 claims abstract description 31
- 210000000582 semen Anatomy 0.000 claims abstract description 20
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 14
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract description 14
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 14
- 244000068988 Glycine max Species 0.000 claims abstract description 12
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000008367 deionised water Substances 0.000 claims abstract description 8
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 8
- 238000000855 fermentation Methods 0.000 claims abstract description 8
- 230000004151 fermentation Effects 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 238000001694 spray drying Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000000746 purification Methods 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 238000004108 freeze drying Methods 0.000 claims abstract description 4
- 238000010298 pulverizing process Methods 0.000 claims abstract description 4
- 238000002137 ultrasound extraction Methods 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 235000020712 soy bean extract Nutrition 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 150000002333 glycines Chemical class 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 2
- 201000005569 Gout Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000037157 Azotemia Diseases 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000009852 uremia Diseases 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- XGYCWCIGCYGQFU-UHFFFAOYSA-N 1,2-thiazolidine 1,1-dioxide Chemical compound O=S1(=O)CCCN1 XGYCWCIGCYGQFU-UHFFFAOYSA-N 0.000 description 1
- FSSPGSAQUIYDCN-UHFFFAOYSA-N 1,3-Propane sultone Chemical compound O=S1(=O)CCCO1 FSSPGSAQUIYDCN-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种降尿酸药物，包括黄豆发酵提取物、车前子提取物和东革阿里提取物。制作方法的具体步骤为，一：将黄豆粉碎后，发酵完成后提取分离纯化，提取分离纯化后的液体减压浓缩，剩余浆状物冻干得到黄豆发酵提取物；二：将车前子粉碎，加去离子水，超声波提取分离纯化，剩余液体减压浓缩后喷雾干燥得到车前子提取物；三：将东革阿里粉碎，加去离子水，超声波提取分离纯化，剩余液体减压浓缩后喷雾干燥得到东革阿里提取物；四：车前子提取物和东革阿里提取物按照1:10比例混合，得到车前子东革阿里混合提取物；五：将黄豆发酵提取物与车前子东革阿里混合提取物按照质量比1‑2：2‑3的比例混合。
Description
技术领域
本发明涉及医药技术领域，具体涉及一种降尿酸药物及其制作方法。
背景技术
尿酸是人类嘌呤化合物的终末代谢产物。嘌呤代谢紊乱导致高尿酸血症。本病患病率受到多种因素的影响，与遗传、性别、年龄、生活方式、饮食习惯、药物治疗和经济发展程度等有关。高尿酸血症是痛风的发病基础。痛风是一种由于嘌呤生物合成代谢增加，尿酸产生过多或因尿酸排泄不良而致血中尿酸升高，尿酸盐结晶沉积在关节滑膜、滑囊、软骨及其他组织中引起的反复发作性炎性疾病。它是由于单钠尿酸盐结晶(MSU)或尿酸在细胞外液形成超饱和状态，使其晶体在组织中沉积而造成的一组异源性疾病。本病以关节液和痛风石中可找到有双折光性的单水尿酸钠结晶为其特点。其临床特征为：高尿酸血症及尿酸盐结晶、沉积所致的特征性急性关节炎、痛风石、间质性肾炎，严重者见关节畸形及功能障碍，常伴尿酸性尿路结石。
当前，国内外降尿酸产品主要以西药为主，市场上治疗高尿酸血症的主要药物包括：非布司他、丙舒磺、苯溴马隆、别嘌醇、秋水仙碱。其中非布司他、别嘌醇为黄嘌呤氧化酶抑制剂，降低体内的尿酸产生而达到降尿酸的目的，副作用为对心脑血管存在明显损伤，导致心脑血管疾病的发生；苯溴马隆的作用原理为通过扩张肾小球达到排泄尿酸而降低血尿酸浓度，副作用大，易导致尿毒症的发生；丙舒磺及秋水仙碱为痛风急发期的用药，副作用特别明显。
发明内容
本发明针对现有技术的不足，提出一种利用食药两用天然产物为原料，经发酵、提取、分离纯化等操作，获得活性成分，科学配方组合，具有降低血尿酸浓度的降尿酸药物及其制作方法，具体技术方案如下：
一种降尿酸药物，包括黄豆发酵提取物、车前子提取物和东革阿里提取物。
作为优化：其中车前子提取物和东革阿里提取物的比例为1:10。
作为优化：所述车前子提取物和东革阿里提取物混合物与所述黄豆发酵提取物按照质量比为1-2：2-3。
中医观点认为，一般情况下，高尿酸血症——痛风症候为湿热痹症。高尿酸对人体脏腑器官的肾脏、肝脏、脾脏损伤较为明显。本组合配方中：黄豆提取物活性成分为纳豆激酶，具有保护人体脏腑器官、溶解血栓、调节人体代谢平衡的功效；车前子提取物具有清热化湿化痰、清肝明目、利水通淋的功效；东革阿里提取物具有补肾强身、利湿退黄、消除疲劳、增强免疫力等功效。通过这样的食药两用天然产物提取物组合，可有效加速尿酸排泄、让代谢达到平衡。
一种降尿酸药物的制作方法，具体步骤为，
步骤一：将黄豆粉碎后，加入水后加热煮沸灭菌后，加入枯草杆菌，在25℃的环境下发酵，发酵完成后提取分离纯化，提取分离纯化后的液体减压浓缩，剩余浆状物冻干得到黄豆发酵提取物；
步骤二：将车前子粉碎，加去离子水，超声波提取分离纯化，剩余液体减压浓缩后喷雾干燥得到车前子提取物；
步骤三：将东革阿里粉碎，加去离子水，超声波提取分离纯化，剩余液体减压浓缩后喷雾干燥得到东革阿里提取物；
步骤四：将步骤二、步骤三中得到的车前子提取物和东革阿里提取物按照1:10比例混合，得到车前子东革阿里混合提取物；
步骤五：将黄豆发酵提取物与车前子东革阿里混合提取物按照质量比1-2：2-3的比例混合。
本发明的有益效果为：1、快速安全降低血尿酸浓度，预防痛风及缓解痛风发作期的不适症状；2、保护肾功，预防高尿酸所导致的尿毒症发生及尿毒症前期症状(肌酐值<600)的逆转。
具体实施方式
本发明的较佳实施例进行详细阐述，以使本发明的优点和特征能更易于被本领域技术人员理解，从而对本发明的保护范围做出更为清楚明确的界定。
一种降尿酸药物，包括黄豆发酵提取物、车前子提取物和东革阿里提取物。其中车前子提取物和东革阿里提取物的比例为1:10，所述车前子提取物和东革阿里提取物混合物与所述黄豆发酵提取物按照质量比为1-2：2-3。
上述降尿酸药物的制作方法，具体步骤为，
步骤一：将黄豆粉碎后，加入水后加热煮沸灭菌后，加入枯草杆菌，在25℃的环境下发酵，发酵完成后提取分离纯化，提取分离纯化后的液体减压浓缩，剩余浆状物冻干得到黄豆发酵提取物；
步骤二：将车前子粉碎，加去离子水，超声波提取分离纯化，剩余液体减压浓缩后喷雾干燥得到车前子提取物；
步骤三：将东革阿里粉碎，加去离子水，超声波提取分离纯化，剩余液体减压浓缩后喷雾干燥得到东革阿里提取物；
步骤四：将步骤二、步骤三中得到的车前子提取物和东革阿里提取物按照1:10比例混合，得到车前子东革阿里混合提取物；
步骤五：将黄豆发酵提取物与车前子东革阿里混合提取物按照质量比1-2：2-3的比例混合。
案例1：黄某，男，47岁，血尿酸560左右，痛风发作频率1次/月，服用本食药两用组合物一个月，医院检测结果为血尿酸<330，体感舒爽无反弹，效果满意。
案例2：杨某，男，43岁，血尿酸720左右，肌酐580。服用本食药两用组合物1月，医院检验结果为血尿酸<390，肌酐95。全身浮肿状况完全消失，精神状态良好，易倦怠症状完全消失。
Claims (4)
1.一种降尿酸药物，其特征在于：包括黄豆发酵提取物、车前子提取物和东革阿里提取物。
2.根据权利要求1所述降尿酸药物，其特征在于：其中车前子提取物和东革阿里提取物的比例为1:10。
3.根据权利要求2所述降尿酸药物，其特征在于：所述车前子提取物和东革阿里提取物混合物与所述黄豆发酵提取物按照质量比为1-2：2-3。
4.一种降尿酸药物的制作方法，其特征在于：具体步骤为，
步骤一：将黄豆粉碎后，加入水后加热煮沸灭菌后，加入枯草杆菌，在25℃的环境下发酵，发酵完成后提取分离纯化，提取分离纯化后的液体减压浓缩，剩余浆状物冻干得到黄豆发酵提取物；
步骤二：将车前子粉碎，加去离子水，超声波提取分离纯化，剩余液体减压浓缩后喷雾干燥得到车前子提取物；
步骤三：将东革阿里粉碎，加去离子水，超声波提取分离纯化，剩余液体减压浓缩后喷雾干燥得到东革阿里提取物；
步骤四：将步骤二、步骤三中得到的车前子提取物和东革阿里提取物按照1:10比例混合，得到车前子东革阿里混合提取物；
步骤五：将黄豆发酵提取物与车前子东革阿里混合提取物按照质量比1-2：2-3的比例混合。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110794132.6A CN113425765A (zh) | 2021-07-14 | 2021-07-14 | 一种降尿酸药物及其制作方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110794132.6A CN113425765A (zh) | 2021-07-14 | 2021-07-14 | 一种降尿酸药物及其制作方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113425765A true CN113425765A (zh) | 2021-09-24 |
Family
ID=77760326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110794132.6A Pending CN113425765A (zh) | 2021-07-14 | 2021-07-14 | 一种降尿酸药物及其制作方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113425765A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114041593A (zh) * | 2021-12-01 | 2022-02-15 | 中科创导(山东)生物科技有限公司 | 一种降尿酸的复合寡糖酵素酶及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511641A (zh) * | 2016-11-16 | 2017-03-22 | 新时代健康产业（集团）有限公司 | 一种具有治疗痛风功效的青梅纳豆组合物及其制备方法 |
| CN107303303A (zh) * | 2016-04-22 | 2017-10-31 | 北京罗瑞生物科技有限公司 | 制备东革阿里有效成分及组合应用 |
| CN107897719A (zh) * | 2017-12-01 | 2018-04-13 | 凯风新农（北京）科技有限公司 | 一种纳豆复合制剂及其制备方法 |
| CN110496143A (zh) * | 2018-05-17 | 2019-11-26 | 天津中医药大学 | 东革阿里提取物、其制备方法、以及其用途 |
-
2021
- 2021-07-14 CN CN202110794132.6A patent/CN113425765A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107303303A (zh) * | 2016-04-22 | 2017-10-31 | 北京罗瑞生物科技有限公司 | 制备东革阿里有效成分及组合应用 |
| CN106511641A (zh) * | 2016-11-16 | 2017-03-22 | 新时代健康产业（集团）有限公司 | 一种具有治疗痛风功效的青梅纳豆组合物及其制备方法 |
| CN107897719A (zh) * | 2017-12-01 | 2018-04-13 | 凯风新农（北京）科技有限公司 | 一种纳豆复合制剂及其制备方法 |
| CN110496143A (zh) * | 2018-05-17 | 2019-11-26 | 天津中医药大学 | 东革阿里提取物、其制备方法、以及其用途 |
Non-Patent Citations (1)
| Title |
|---|
| 周全胜: "车前子的妙用", 《家庭医学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114041593A (zh) * | 2021-12-01 | 2022-02-15 | 中科创导(山东)生物科技有限公司 | 一种降尿酸的复合寡糖酵素酶及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102228285B (zh) | 一种调理脾胃、缓解便秘的保健饮料及其制备方法 | |
| CN104651434A (zh) | 一种骨肽溶液的制备方法 | |
| CN113425765A (zh) | 一种降尿酸药物及其制作方法 | |
| CN106867858A (zh) | 一种保健醋的制备方法 | |
| CN106432549A (zh) | 一种从动物肺中提取肝素钠的方法及该肝素钠 | |
| CN106889393A (zh) | 一种火麻仁蛋白功能饮料及其制备方法 | |
| CN107625095A (zh) | 一种具有排毒去湿功效的龟苓膏及其制备工艺 | |
| WO2015190872A1 (ko) | 스피루리나 추출물을 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물 | |
| TWI395590B (zh) | 相思樹抽出物及其成分作為抑制黃嘌呤氧化酶之應用 | |
| JP2004323420A (ja) | 新規なα−グルコシダーゼ阻害活性を有する物質およびこれを含有する食品 | |
| CN106472918A (zh) | 一种石斛抗氧化饮品 | |
| CN113318183A (zh) | 一种含迷迭香的降尿酸组合物、降尿酸保健品及降尿酸药物 | |
| CN100389187C (zh) | 一种银杏酒的制备方法 | |
| CN107287026B (zh) | 一种牡丹籽油脱酸提取方法 | |
| CN105038946A (zh) | 一种牡丹精油的超临界co2萃取方法 | |
| CN104997669A (zh) | 一种具有洁面嫩肤和改善肌肤新陈代谢的组合物 | |
| CN102894317A (zh) | 一种醋泡大蒜的生产工艺及生产的大蒜醋、醋大蒜 | |
| CN101348814A (zh) | 一种利用蛋白质等电点提高硫酸软骨素质量的方法 | |
| CN101524370B (zh) | 一种猪脑蛋白水解物的生产工艺 | |
| CN114053316A (zh) | 一种脱脂月见草籽提取物及其应用 | |
| CN109393066A (zh) | 一种复合型浓香芝麻油 | |
| CN107156409A (zh) | 一种降低尿酸防治痛风的蜜拉圣果糖浆及其生产工艺 | |
| CN110404046A (zh) | 一种制备抗痛风植物葵花盘提取物活性肽泡腾片的方法 | |
| JP2007015941A (ja) | 米を除く穀類及び豆類を原料とする寿命延長剤 | |
| CN105400673A (zh) | 一种中药酿造滋补保健酒及活参酒和制备工艺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210924 |
|
| RJ01 | Rejection of invention patent application after publication |